

**NEUROENDOCRINE  
DISEASE ORIENTED GROUP  
AGENDA  
**OPEN SESSION****

VENUE: ROSSETTI ROOM, CHELSEA HOTEL, TORONTO

DATE SATURDAY, APRIL 30<sup>th</sup>, 2016

TIME: 15:15 – 16:00 pm

**CHAIRS: DR. TIM ASMIS & DR. SIMRON SINGH**

- 
- 15:15 WELCOME AND INTRODUCTION **DR. T. ASMIS / DR. S. SINGH**
- 15:20 ACTIVE TRIALS FOR UPDATE/DISCUSSION
- NEC.3 (ALLIANCE 021202): PROSPECTIVE RANDOMIZED PHASE II TRIAL OF PAZOPANIB  
VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE CARCINOID TUMORS DR. T. ASMIS**
- 15:25 CONCEPTS IN DEVELOPMENT
- HIGH DOSE LANREOTIDE IN GEP NETS **DR. S. SINGH**
- 15:40 INTERGROUP TASK FORCE UPDATE **DR. T. ASMIS**
- PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED,  
PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMORS AFTER FAILURE OF PRIOR THERAPY
- 15:50 COMMNETS – COMMONWEALTH NEUROENDOCRINE TUMOUR COLLABORATION **DR. S. SINGH**
- 16:00 CLOSING REMARKS